Statistic Problems

      The conflicting results from the GISSI-P and OMEGA trials (see ECC5971 Assignment One) prompted a large international pharmaceutical company to conduct a new well-designed RCT (SQUID-THIS) with their own new formulation of Giant-Squid-Oil containing Omega-3. The results over a period of three years indicated an improvement in all-cause mortality, non-fatal MI and non-fatal stroke, although the latter two outcomes did not reach statistical significance, summarised in Table 1. Table 1: Results of the SQUID-THIS trial  Giant-Squid-Oil versus placeboRR (95%CI) All cause death 0.82 (0.66, 0.98)Non-fatal myocardial infarction 0.88 (0.75, 1.04)Non-fatal stroke 0.92 (0.79, 1.07) Based on the promising results (and the extremely high cost of hunting giant-squids in the ocean depths) the pharmaceutical company has instructed you to determine the cost-effectiveness of their new formulation of Giant-Squid-Oil to support an application to the PBAC for listing on the PBS as soon as possible!   prepare a modelled cost-effectiveness analysis to present to the PBAC.   “what is the modelled cost-effectiveness of Giant-Squid-Oil compared to no adjuvant therapy for secondary prevention after myocardial infarction in patients treated with standard therapies, over 10 years, from the perspective of the Commonwealth Government?”